Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL499609 | 1.00 | PDK2 (0.37) | PDK2HTR2CSLC6A4CCNE2CCNE1 | |
| SCHEMBL10253752 | 0.95 | PDK2 (0.36) | PDK2HTR2CSLC6A4CCNE2CCNE1 | |
| Trifluoroacetic Acid SCHEMBL4789527 | 0.89 | SLC6A9 (0.33) | PDK2HTR2CSLC6A9KIF11KCNH2 | |
| SCHEMBL4789528 | 0.87 | SLC6A9 (0.30) | SLC6A9 | |
| SCHEMBL499028 | 0.87 | PDK2 (0.36) | PDK2HTR2CSLC6A4CCNE2CCNE1 | |
| SCHEMBL499029 | 0.87 | PDK2 (0.36) | PDK2HTR2CSLC6A4CCNE2CCNE1 | |
| SCHEMBL499226 | 0.84 | SLC6A9 (0.34) | SLC6A9KIF11KCNH2 | |
| SCHEMBL8084228 | 0.81 | PDK2 (0.36) | PDK2HTR2CSLC6A4CCNE2CCNE1 | |
| SCHEMBL499353 | 0.75 | SLC6A9 (0.35) | PDK2SLC6A9KCNH2 | |
| SCHEMBL499980 | 0.68 | HPGD (0.34) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | PDK2 2610/4885HTR2C 2973/4885SLC6A4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.